Rapid Diagnostic Tests as a Source of Dengue Virus RNA for Envelope Gene Amplification: 
A Proof of Concept

Sarah Cassidy-Seyoum,1,2 Manivanh Vongsouvath,1 Onanong Sengvilapaeseuth,1 Malee Seephonelee,1 Tehmina Bharucha,1,3 Xavier de Lamballerie,4 Paul N. Newton,1,3,5 and Audrey Dubot-Péres1,4,5*

1Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao P.D.R; 2London School of Hygiene and Tropical Medicine, London, United Kingdom; 3Division of Infection and Immunity, University College London, London, United Kingdom; 4Unité des Virus Emergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France; 5Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom

Abstract. Molecular epidemiological data are key for dengue outbreak characterization and preparedness. However, sparse Dengue virus (DENV) molecular information is available in Laos because of limited resources. In this proof-of-concept study, we evaluated whether DENV1 RNA extracted from rapid diagnostic tests (RDTs) could be amplified and sequenced. The protocol for envelope gene amplification from RNA purified from RDTs was first assessed using viral isolate dilutions then conducted using 14 dengue patient sera. Envelope gene amplification was successful from patient sera with high virus titer, as was sequencing but with lower efficiency. Hence, based on our results, RDTs can be a source of DENV1 RNA for subsequent envelope gene amplification and sequencing. This is a promising tool for collecting molecular epidemiology data from rural dengue-endemic areas. However, further investigations are needed to improve assay efficiency and to assess this tool’s level of efficacy on a larger scale in the field.

In more than 100 endemic countries, there are an estimated 390 million Dengue virus (DENV) infections a year, of which 96 million are symptomatic.1,2 DENV (enveloped, single-stranded RNA) infection mostly results in a subclinical or mild febrile illness, but may occasionally cause severe dengue and lead to death. In Laos, where 3.9 million people are at risk of infection, dengue is endemic, is epidemic during the rainy season, and affects urban and rural populations.3–6

There are four antigenically related serotypes—DENV1–4. There is evidence to suggest that DENV serotypic and genotypic factors, such as virulence of specific serotypes and strains and the introduction of a new serotype or genotype, play roles in patient outcomes, emergence of outbreaks, and their severity.7–10 Therefore, molecular data can be used for epidemic modeling and outbreak preparedness. However, limited data on dengue molecular epidemiology in Laos are available, although it is known that all four DENV serotypes (DENV1–4) circulate.4–6,11–14

This lack of molecular epidemiological data is a result of the limited number of institutions in Laos with molecular laboratory facilities. In addition, these specialized laboratories are all located in the capital, Vientiane, and there are limited cold chain facilities to transport samples from rural areas.15 In those areas, the use of immunochromatographic rapid diagnostic tests (RDTs) for dengue diagnosis has recently expanded. Therefore, as a potential solution, Vongsouvath and others showed that RDTs, which are transportable at room temperature, can be used as a source for DENV RNA for small-fragment amplification using real-time reverse transcription polymerase chain reaction (RT-qPCR).15–17

Hence, using the Vongsouvath et al. study as a foundation, this proof-of-concept study aimed to determine whether DENV RNA of good enough quality and quantity can be extracted from RDTs to amplify and then sequence the full DENV envelope gene (Env). Access to the Env sequence would allow DENV strain characterization by phylogenetic analysis.10,18

We first evaluated RT-PCR assays for large-fragment amplification of RNA extracted from RDTs using dilutions of a DENV1 isolate. Second, we tested the procedure on patient samples. This tool was assessed on DENV1—the serotype that has historically caused the largest dengue burden in Laos. The DENV1 isolate used in this study was previously obtained by virus isolation on cell culture.9 Replicate aliquots of 10-fold serial dilutions were performed using minimum essential medium (Gibco, ThermoFisher, Waltham, MA) until the limit of detection as determined by RT-qPCR (10^-1 to 10^-6).

Patient samples collected between July and October 2010 as part of a dengue molecular epidemiology study at Mahosot Hospital in Vientiane were used for this proof-of-concept study.5 Written informed consent for use of patient samples was obtained from all recruited patients or responsible guardians. Ethics approval was obtained from the Lao National Ethics Committee for Health Research and the Oxford Tropical Research Ethics Committee. Serum aliquots stored at -80°C from 14 patients were selected based on availability and initial RT-qPCR results; six lower titer samples and eight higher titer samples were selected.

Aliquots of each viral dilution and patient sample were loaded onto RDTs for subsequent RNA extraction. As previously described, 100 μL of the viral dilutions or patient samples was loaded on the NS1 side of the Standard Diagnostics BIOLINE Dengue Duo RDT (Standard Diagnostics, Gyeonggi-do, Republic of Korea).15 Subsequently, the completely dry sample pad was cut out and submitted for RNA purification using QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to previously published procedure.15 As reference, 140 μL of each sample was also directly extracted using QIAamp Viral RNA Mini Kit following the manufacturer’s instructions.

A pan-dengue RT-qPCR was used for DENV RNA detection and quantification, as previously described.19 SuperScript III Platinum One-Step qRT-PCR Kit (ThermoFisher) was used
following the manufacturer’s instruction in a final volume of 25 μL, using 0.4 μM of each primer and 0.16 μM of probe with 5 μL of RNA. Ten-fold dilutions of the RNA synthetic control were used as standards for quantification (2.0 × 10 to 2.0 × 10^2 copies/μL). Negative controls (no template) were added at each run.

For the large-fragment amplification of the full DENV1 Env, three sets of primers were designed by Dubot-Pérès et al.4 Conventional RT-PCRs were conducted for each primer set using the Access RT-PCR system (Promega, Madison, WI) following the manufacturer’s instruction in a final volume of 50 μL. The determined parameters used for optimal amplification for each primer set are displayed in Table 1.

All RT-PCR products with successful amplification (a clear band at expected size on agarose gel) were sent to Macrogen Inc. (Seoul, South Korea) for purification and Sanger sequencing for both forward and reverse directions. The obtained sequences of the three fragments were analyzed using 4Peaks software (version 1.8, Mekentosj, Lisbon, Portugal) and assembled into a consensus sequence using Mega7 software (Pennsylvania State University, State College, PA).20

The three RT-PCR assays for Env amplification (Env RT-PCRs) were performed on RNA directly extracted from the dilutions of the DENV1 isolate. Successful amplification was obtained for all dilutions, except the last one, 10^-6 (Table 2). The DENV1 isolate dilutions 10^-3, 10^-4, and 10^-5 were then

---

### Table 1

| Condition | Primer set 1 | Primer set 2 | Primer set 3 |
|-----------|--------------|--------------|--------------|
| Primer final concentration in the RT-PCR mix | 0.4 μM | 0.4 μM | 0.6 μM |
| MgSO4 final concentration in the RT-PCR mix | 2 mM | 1 mM | 1 mM |
| Final concentration for each dNTP in the RT-PCR mix | 0.2 mM | 0.2 mM | 0.2 mM |
| Annealing temperature | 59.4°C | 42°C | 59.4°C |

Preliminary experiments (data not shown) were performed to determine the optimal primer and MgSO4 concentrations and annealing temperature for each primer set. Optimal conditions resulting from these experiments are displayed in the table. The thermal cycling consisted of 45°C for 45 minutes, 94°C for 2 minutes, 40 × (94°C for 30 seconds, annealing temperature for 1 minute, and 68°C for 2 minutes), and 68°C for 7 minutes.

---

### Table 2

| Viral dilutions | Direct RNA extraction | RNA extracted from RDTs |
|-----------------|----------------------|-------------------------|
|                | RT-qPCR (Cq)*        | Env amplification†      | RT-qPCR (Cq)‡          | Env amplification† |
|                 | RNA co/μL            | PS 1 PS 2 PS 3 PS 1 PS 2 PS 3 | PS 1 PS 2 PS 3 PS 1 PS 2 PS 3 |
| 10^-1           | 18.3 3.6 × 10^5      | Good Good               | Good Good Good Good    |
| 10^-2           | 22.0 2.9 × 10^6      | Good Good               | Good Good Good Good    |
| 10^-3           | 25.1 3.5 × 10^7      | Good Good               | Good Good Good Good    |
| 10^-4           | 29.1 2.2 × 10^8      | Good Good               | Good Good Good Good    |
| 10^-5           | 32.3 2.5 × 10        | Good Good               | Good Good Good Good    |
| 10^-6           | 35.8 2.3             | - - - -                 | - - - - - - -         |
| 10^-7           | - -                  | - - - -                 | - - - - - - -         |
| 10^-8           | - -                  | - - - -                 | - - - - - - -         |
| NC              | - -                  | 36.65 - -               | - - - - - - -         |

co = copies; Env = envelope gene; NC = negative control, culture medium used for dilutions; PS = primer set.

* Triplicate RT-qPCRs were conducted on the direct RNA extract, and the mean Cq values are displayed.

† For direct RNA extractions, 10 μL of the PCR product and 10 μL of the ladder were loaded on 1% agarose gel for primer set 1, 2, and 3 Env RT-PCRs. For RDT extractions, 20 μL of the PCR product and 20 μL of the ladder were loaded on 1% agarose gel. A “good” band is one whose intensity was comparable to or stronger than the intensity of the 1,000-bp band of HyperLadder II (corresponding to 20 ng/μL) loaded on the same gel. A band was classified as “weak” when the band was of faint intensity.

‡ Duplicate RT-qPCRs were conducted on the RNA extracted from RDTs, and the mean Cq values are displayed.
loaded on RDTs in triplicate. Env RT-PCRs performed on the RNA extracted from those RDTs were successful only for the highest RNA concentration dilution: 10⁻³ (Table 2). For two of the three primer sets, amplification was successful for all triplicates; however, for one primer set, only two of the three triplicates were successfully amplified.

Based on the preceding results, it was expected that only patient samples with a substantial virus titer could be successfully amplified after RDT extraction. Therefore, to test this hypothesis, samples of varying virus titers were selected according to their originally obtained Cq values. Env amplification was successful for the RDT extract for three patients with the highest viral load (> 4.1 × 10³ copies/μL corresponding to 2.3 × 10⁶ copies/mL of blood) (Table 3). Sanger sequencing of the corresponding PCR products resulted in full (1,485 bp) and partial (983 bp) Env sequences for the two patients for whom good amplifications were obtained (Table 3, P1 and P14).

For the first time, a DENV Env sequence was obtained from RDTs experimentally loaded with dengue patient sera. Using RDTs as a source of RNA for phylogenetic analyses would remove the cold chain limitation of using whole samples. Given the expanded use of dengue RDTs among Lao communities, this tool would enable access to DENV molecular information from previously inaccessible areas.

| Patient Sample ID | Direct RNA Extraction | RNA extracted from RDTs |
|------------------|-----------------------|-------------------------|
|                  | RT-qPCR (Cq) | RNA copies/μL | Env Amplification* | RT-qPCR (Cq) | RNA copies/μL | Env Amplification* | Overall Sequencing Result† |
|                  | Primer Set 1 | Primer Set 2 | Primer Set 3 | Primer Set 1 | Primer Set 2 | Primer Set 3 |                 |
| P1               | 18.8        | 2.2 × 10⁶    | Good         | Good         | Good         | 25.2         | 1.3 × 10⁴     | Good         | Good         | Good         | Partial (983 bp) |
| P2               | 37.2        | 9 × 10⁻⁶     | -            | -            | -            | 38.9         | 2.0 × 10⁻⁴    | -            | -            | -            |
| P3               | -           | -            | -            | -            | -            | 39.4         | 2.0 × 10⁻⁴    | -            | -            | -            |
| P4               | 39.5        | 2 × 10⁻⁶     | -            | -            | -            | -            | -            | -            | -            | -            |
| P5               | 33.0        | 2.7 × 10⁻¹   | -            | -            | -            | 36.1         | 2.3           | -            | -            | -            |
| P6               | -           | -            | -            | -            | -            | -            | -            | -            | -            | -            |
| P7               | 28.2        | 1.2 × 10³    | Good         | Good         | Good         | 31.0         | 1.3 × 10⁵    | -            | -            | -            |
| P8               | 29.3        | 5.1 × 10⁻²   | -            | -            | -            | 31.4         | 9.6 × 10⁻¹   | -            | -            | -            |
| P9               | 26.7        | 4.1 × 10³    | Good         | Weak         | Good         | 31.1         | 1.2 × 10⁵    | Weak         | -            | Weak         | No sequence   |
| P10              | -           | -            | -            | -            | -            | 37.1         | 1.0           | -            | -            | -            |
| P11              | 34.6        | 7.5          | -            | -            | -            | -            | -            | -            | -            | -            |
| P12              | -           | -            | -            | -            | -            | -            | -            | -            | -            | -            |
| P13              | -           | -            | -            | -            | -            | 35.9         | 2.7           | -            | -            | -            |
| P14              | -           | -            | -            | -            | -            | 25.9         | 7.7 × 10⁻³   | Good         | Good         | Good         | Full (1,485 bp) |

Env = envelop gene; NTC = no template control.
- "-" stands for no Cq value or Cq > 40 for RT-qPCR and for no band for conventional RT-PCR. "Full" stands for the full envelope gene sequence from all three primer sets and "partial" stands for a partial envelope sequence. Gray shading indicates that RT-PCR was not performed.
- "-" Five microliter of the PCR product and 5 μL of the ladder were loaded on agarose gel for primer set 1, 2, and 3 Env RT-PCRs. A “good” band is one whose intensity was comparable to or stronger than the intensity of the 1,000-bp band of HyperLadder II (corresponding to 20 ng/μL) loaded on the same gel. A band was classified as “weak” when the band was of faint intensity.
- †Sequences reported are only those of high-quality chromatograms. Reported base pair (bp) numbers are the length of the consensus sequences from the assembly of sequences from both forward and reverse directions for the three sets of primers.
In an epidemic context, this method in its current form could be used to characterize the strain causing an outbreak through Env sequencing from patients with the highest viremia. In an outbreak, most patients are infected with the same strain. Phylogenetic analyses based on Env sequences will provide evidence regarding the origin of the DENV strain. Enhanced DENV molecular surveillance even of just high viremia patients would allow for tracking of strains and genotypes circulating country-wide over time and space. Such surveillance may enable the identification of the introduction of new strains and to better understand the dynamics of DENV strain circulation within the country and across borders. Those molecular data could be used in dengue epidemic modeling to help predict outbreaks, allowing for enhanced prevention and preparedness.

There are several factors and limitations to consider when discussing our findings and the viability and feasibility of this tool. Further optimization of the conventional RT-PCR assay and sequencing are likely to permit successful amplification for patients with lower viral loads. First, a simple adjustment would be to increase the volume of the RNA template used for Env RT-PCRs. Second, long-range PCR assays may be more efficient at amplifying the RDT-extracted RNA. Finally, cloning of amplicons or using high-throughput sequencing may improve sequencing results.

Other factors limiting the efficiency of the technique include a potential loss of RNA when extracting from RDTs versus direct extraction, and the storage duration of the samples used. The samples were collected 7 years before this study and stored at –80°C; therefore, RNA degradation over time is likely to have affected amplification and sequencing results. Hence, testing the procedure with prospectively collected patient samples is required to determine if better results can be obtained.

Ideally, our protocol should be tested on numerous RDTs from the field that have been stored and transported at room temperature to ascertain whether the use of RDTs as a source of RNA for amplification is practically possible on a large scale. If temperature were to be a limiting factor, additional techniques, such as adding RNAlater to the RDTs after being read, could mitigate potential RNA degradation. In addition, the protocols need to be tested on the remaining three serotypes and on other RDT brands that may be used across the country. If the RT-PCR assay sensitivity were increased and the approach were more thoroughly tested on RDTs from the field, using RDTs for sample collection would enable access to more dengue epidemiological data, producing a more complete picture of the complex DENV strain dynamics in Laos. This would likely improve the accuracy of outbreak forecasting at national and regional levels. Therefore, this proof-of-concept study showed that the use of RDTs as a source of RNA for DENV molecular epidemiology analyses is a promising tool that merits further investigation.

Received October 17, 2018. Accepted for publication May 6, 2019.

Acknowledgments: We are very grateful to the patients and to Assoc. Prof. BouAthaphany Bouxouvei, director of Mahosot Hospital; to Assoc. Prof. Bounnack Saysanasongkham, director of Department of Health Care, Ministry of Health; to H.E. Assoc. Prof. Bounkong Syhavong, minister of health, Lao PDR; to the staff of the Infectious Disease Center and Microbiology Laboratory, especially Viengmon Davong, Mayfong Mayxay, Vilada Chansamouth, Koueko Phommone, and Sayaphet Rattanavong; to the Institut de Recherche pour le Développement (IRD); and to the staff of the Unité des Virus Émergents for their very kind help and support.

Financial support: This study was funded by the Wellcome Trust of Great Britain, the Institute of Research for Development, and Aix-Marseille University. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclosure: Newton reports grants from Wellcome Trust during the conduct of the study. All the other authors have nothing to disclose.

Authors’ addresses: Sarah Cassidy-Seyoum, Lyon School of Hygiene and Tropical Medicine, London, United Kingdom, E-mail: sarah.cassidy-seyoum1@alumni.lshtm.ac.uk. Manivanh Yongpovath, Onanong Sengvilaipaseuth, and Malee Seephonelee, Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao P.D.R., E-mails: manivanh@tropmedres.ac, onanong@tropmedres.ac, and malee@tropmedres.ac. Tehmina Bharucha, Division of Infection and Immunity, University College London, London, United Kingdom, E-mail: t.bharucha@doctors.org.uk. Xavier de Lamballerie and Audrey Dubot-Pérès, Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Faculté de Médecine, Marseille, France, E-mail: xavier.de-lamballerie@univ-amu.fr and audrey@tropmedres.ac. Paul N. Newton, Center for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom, E-mail: paul@tropmedres.ac.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. World Health Organization (WHO), 2017. Dengue and severe dengue. Available at http://www.who.int/mediacentre/factsheets/fs117/en/. Accessed July 20, 2017.

2. Bhatt S et al., 2013. The global distribution and burden of dengue. Nature 496: 504–507.

3. Khampapongpane B, Lewis HC, Ketmayaoon P, Phonekeo D, Somoulay V, Khamsing A, Phengxay M, Sisouk T, Yongprachan P, Bryant JE, 2014. National dengue surveillance in the Lao People’s Democratic Republic, 2006-2012: epidemiological and laboratory findings. West Pac Surveill Response J 5: 7–13.

4. Dubot-Péres A et al., 2013. An epidemic of dengue-1 in a remote village in rural Laos. PLoS Negl Trop Dis 7: e2360.

5. Castonguay-Vanier J et al., 2018. Molecular epidemiology of dengue viruses in three provinces of Lao PDR, 2006–2010. PLoS Negl Trop Dis 12: e0006203.

6. Mayxay M et al., 2011. Predictive diagnostic value of the tourniquet test for the diagnosis of dengue infection in adults: accuracy of the tourniquet test for the diagnosis of dengue. Trop Med Int Health 16: 127–133.

7. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn C, Scott RM, Burke DS, Hoke CH, Innis BL, Vaughn DW, 2003. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 68: 191–202.

8. Balmaseda A et al., 2006. Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg 74: 449–456.

9. Dash PK, Parida MM, Saxena P, Abhyankar A, Singh CP, Tewari KN, Jana AM, Sekhar K, Rao PVL, 2006. Reemergence of dengue virus type-3 (subtype-III) in India: implications for increased incidence of DHF & DSS. Virology J 3: 55.

10. Lee K-S, Lo S, Tan SS-Y, Chua R, Tan L-K, Xu H, Ng L-C, 2012. Dengue virus surveillance in Singapore reveals high viral diversity through multiple introductions and in situ evolution. Infect Genet Evol 12: 77–85.

11. Lao M et al., 2014. Co-circulation of dengue virus type 3 genotypes in Vientiane capital, Lao P.D.R. PLoS One 9: e115569.
12. Fukunaga T, Phommasack B, Bounlu K, Saito M, Tadano M, Makino Y, Kanemura K, Arakaki S, Shinjo M, 1993. Epidemiological situation of dengue infection in Lao P.D.R. Trop Med 35: 219–227.

13. Peyerl-Hoffmann G, Schwöbel B, Jordan S, Vamisaveth V, Phetsouvanh R, Christophel EM, Phompida S, Sonnenburg FV, Jelinek T, 2004. Serological investigation of the prevalence of anti-dengue IgM and IgG antibodies in Attapeu Province, South Laos. Clin Microbiol Infect 10: 181–184.

14. Yang H et al., 2015. Molecular characterization and viral origin of the first dengue outbreak in Xishuangbanna, Yunnan Province, China, 2013. Am J Trop Med Hyg 93: 390–393.

15. Vongsouvath M et al., 2016. Using rapid diagnostic tests as a source of viral RNA for dengue serotyping by RT-PCR - a novel epidemiological tool. PLoS Negl Trop Dis 10: e0004704.

16. Sengvilaipaseuth O et al., 2017. Temperature of a dengue rapid diagnostic test under tropical climatic conditions: a follow up study. PLoS One 12: e0170359.

17. Phommasone K, Sengvilaipaseuth O, de Lamballerie X, Vongsouvath M, Phonemixay O, Blacksell SD, Newton PN, Dubot-Pérès A, 2015. Temperature and the field stability of a dengue rapid diagnostic test in the tropics. Am J Trop Med Hyg 93: 33–39.

18. Tang Y, Quintana M, Zhang C, Li T, Sauls D, Putnak R, Alvarado SC, Castro DJ, Matute ML, Lynch JA, 2011. Letter to the editor: molecular genotyping of Dengue Virus Types 2 and 4 from the Guatemalan and Honduran Epidemics of 2007 using the envelope glycoprotein gene. Virus Genes 42: 200–203.

19. Leparc-Goffart I, Baragatti M, Temmam S, Tuiskunen A, Moureau G, Charrel R, de Lamballerie X, 2009. Development and validation of real-time one-step reverse transcription-PCR for the detection and typing of dengue viruses. J Clin Virol 43: 61–66.

20. Kumar S, Stecher G, Tamura K, 2016. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol 33: 1870–1874.